Clinical trials: Human Papillomavirus Virus
Cervical Cancer
Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy.
- Trial name
- NCT00155766
- Testing
- HPV16 E7 peptide-pulsed autologous DCs
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Papilloma Viral Infection
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot.
- Trial name
- NCT01030562
- Where
- 7 sites in United States
- Volunteers
- 1,321 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer, Precancerous Condition
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus.
- Trial name
- NCT00703196
- Testing
- folic acid
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- University of Alabama at Birmingham
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04704908
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 979 people
- Sponsor
- Jun Zhang
Cervical Cancer
Optimizing Cervical Cancer Screening Modalities
This project aims to optimize cervical cancer screening adherence comparing Arm A (VIA) and Arm B self-sampled Human Papilloma Virus (HPV) testing and determine the molecular epidemiology of HPV, persistence level and identify…
- Trial name
- NCT03281135
- Testing
- HPV testing
- Volunteers
- 1,760 people, healthy volunteers welcome
- Sponsor
- Addis Ababa University
Infections, Papillomavirus
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e.
- Trial name
- NCT01290393
- Testing
- Data collection
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia, Cervix Cancer
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
Optical Coherence Tomography (OCT) is a technology using harmless near infra-red light scatter to produce an image. Prior studies with OCT have demonstrated that OCT of the uterine cervix can differentiate between grades of…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Cancer, Cervical Dysplasia, CIN
- Trial name
- PUSHOCTII (NCT01766284)
- Testing
- NIRIS 1300e
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Preventive Oncology International, Inc.
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Recurrent Respiratory Papillomatosis
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions.
- Trial name
- NCT01995721
- Testing
- 4-valent HPV vaccine
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- National Institute of Child Health, Hungary
Human Papilloma Virus, Cervical Cancer
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
The project aims to increase HPV vaccination and cervical cancer screening through a web-based mobile health education program called, Wheel of Wellness (WoW) and a brief negotiated interview (BNI).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer
- Trial name
- NCT03346915
- Testing
- WoW and BNI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Head and Neck Squamous Cell Carcinoma, Human Papillomavirus
The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
This study is designed to refine the aetiological causes of cancers of the head and neck and investigate the ways in which human papillomavirus and life-style factors cause head and neck cancers.
- Trial name
- NCT02126189
- Where
- Australia
- Volunteers
- 600 people
- Sponsor
- Queensland Centre of Excellence for Head and Neck Cancer
Human Papilloma Virus
Engaging Clinical Champions to Improve HPV Vaccination
This trial will compare two ways to improve communication about HPV vaccination in primary care. The research team will work with primary care clinics. Some clinics will receive communication training from an outside expert.
- Trial name
- NCT05736718
- Testing
- Champion Announcement Approach Training, Traditional Announcement Approach Training
- Where
- 2 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Anal Cancer, Cervical Cancer
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients…
- Conditions
- Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00019110
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
- Where
- 6 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
This phase I/II trial tests the safety, side effects, and best dose of alpelisib and whether alpelisib and carboplatin work to shrink tumors in patients with solid tumors or human papillomavirus (HPV) positive squamous cell…
- Conditions
- Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation, Human Papillomavirus-Related Carcinoma
- Trial name
- NCT05472220
- Testing
- Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate
- Sponsor
- Pamela Munster
Human Papilloma Virus (HPV) Vaccine
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the…
- Trial name
- HPV MISTICS (NCT05677360)
- Testing
- HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
This primary goal of this study is to assess whether patient whose parents watch a standardized digital video using the integrated digital approach during a routine office visit are more likely to accept a dose of HPV vaccine…
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02546752
- Testing
- THEO
- Where
- 5 sites in United States
- Volunteers
- 1,306 people
- Sponsor
- Regenstrief Institute, Inc.
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Common Warts, Common Warts (Verruca Vulgaris)
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-5 (NCT07881952)
- Testing
- VP-102
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Verrica Pharmaceuticals Inc.